About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, March 17th, 2017

The QualityStocks
Daily Stock List


Nutritional High International, Inc. (SPLIF)

Promotion Stock Secrets, CFN Media Group, SmallCapVoice, and SECFilings News reported on Nutritional High International, Inc. (SPLIF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Nutritional High International, Inc. centers on developing, manufacturing, and distributing products and nationally recognized brands in the hemp and marijuana-infused products industries. These include edibles and oil extracts for nutritional, medical, and adult recreational use. Nutritional High International works exclusively through licensed facilities in jurisdictions where such activity is permitted and regulated by state law. The Company is headquartered in Toronto, Ontario.

Concerning its Marijuana-Infused Products segment, the Company concentrates on developing, acquiring, and designing Marijuana-Infused Products (MIPs) and Marijuana Concentrate products and brands. In this segment, it is establishing operations in Colorado and Illinois. It is working to expand into additional U.S. States in support of its strategy to establish some of the first nationally-recognized brands for MIPs.

Regarding its Hemp-Infused Products segment, it launched the first product in its Active Hemp category under the brand of “Nutritional Traditions”. Furthermore, pertaining to its Hemp-Infused Products segment, initial distribution will focus on California and Colorado through cannabis-related retail stores: medical marijuana dispensaries, vape lounges and headshops; and Food Supplement retail stores (including vitamin stores, supplement stores, and more).

Nutritional High International’s The Clinic Effingham (TCE) held its grand opening to patients in the State of Illinois on September 20th, 2016. The Clinic Effingham will work with eight different cultivators that grow the flowers and manufacture extracts. The cultivator centers also manufacture gummies, capsules, cookies, brownies, and other infused products.

Nutritional High International announced this past December that Palo Verde LLC successfully passed all local inspections for its project in West Pueblo, Colorado. It has commenced operations. This was the final inspection required to permit Palo Verde to begin its extraction operations. Palo Verde is a private Colorado company. It holds a license to manufacture retail marijuana-infused products within Colorado.

Nutritional High International has leased its Pueblo facility to Palo Verde and provided financing to permit Palo Verde to establish operations. In the future, Palo Verde’s intention is to enter into more agreements with Nutritional High International to have the right to use its brands and intellectual property (IP).

Nutritional High International has completed development of and launched its flagship line of products under the brand name "FLI". The Company is finalizing the formulations for each of the products. They would subsequently be manufactured by Palo Verde at the Company's Pueblo facility. Initially, the FLI line of products will feature the liquid concentrate product.
Recently, Nutritional High International announced that it entered into an agreement to acquire the technology and IP rights to a unique product to be referred to as the “Dab Stick”. The Dab Stick is a dispenser for viscous liquid substances. It can carry roughly 1⁄2 gram of cannabis oil extract designed with the retail consumer and adult use user in mind.

Last month, Nutritional High International and Lakeside Minerals, Inc. announced that they entered into a Letter of Intent dated February 22, 2017. Lakeside will construct medical and adult use cannabis cultivation facilities in Nevada and Colorado, in accordance with applicable state laws.

Nutritional High International, Inc. (SPLIF), closed Friday's trading session at $0.11, up 9.89%, on 144,182 volume with 28 trades. The average volume for the last 60 days is 84,249 and the stock's 52-week low/high is $0.0222/$0.321.

Net Medical Xpress Solutions, Inc. (NMXS)

Hawk Associates, SmallCapVoice, AMIStockReports, and Lions of Wall Street reported previously on Net Medical Xpress Solutions, Inc. (NMXS), and we highlight the Company today, here at the QualityStocks Daily Newsletter.

Net Medical Xpress Solutions, Inc. is a leader in the telemedicine field. The Company provides telemedicine programs for diagnostic and clinical medical services. Net Medical Xpress provides these to mobile companies, urgent cares, and hospitals, trauma centers, imaging centers, jails, nursing homes, corporate health departments and outpatient medical facilities. Net Medical Xpress Solutions has its head office in Albuquerque, New Mexico.

The Company specializes in Web-based medical solutions. By way of its Net Medical Xpress Services, doctors read X-Rays, CT Scans, Ultrasounds, EKGs and more for its clients. Net Medical Xpress provides collaborative tools for quality and secure digital consultations. Being web-based and easy to learn, DICOM files such as X-Rays, Ultrasounds, CTs, MRIs, Echocardiograms, and EKGs are quickly sent and reports returned.

Net Medical Xpress Solutions unveiled in December of 2015 the complete scope of its Telemed Building Blocks technology. This technology allows healthcare facilities to set up their own customized telemedicine infrastructure platforms. The Building Blocks technology represents Net Medical Xpress Solutions’ most expansive technology launch ever.

The Company designed and built modules include Video Conferencing; Digital Paper Application; Records Server Management; Customer Scheduling; and Forms Editor. Additionally, they Secure Chat; Diagnostic Report Builder; Provider Cloud Adapter; Net Medical Santa Fe Linux Operating System; and Net Medical Open Source Linux Database.

Net Medical Xpress Solutions has partnered with eazyScripts, an electronic prescription platform, to provide electronic prescribing services to patients remotely, via telemedicine physicians who serve populations across the country. The eazyScripts platform provides telemedicine physicians with the ability to submit electronic prescriptions, check prescription fill data, secure electronic prior authorization at the touch of a button, reducing inefficiencies and errors.

Net Medical Xpress Solutions has developed a subscription service for its Telemedicine Building Blocks software. This product is available online. It connects to the Internet through any browser. Telemedicine Building Blocks is being used by hospitals and clinics across the U.S.

In the Company’s staffing division, it has brought its permanent database of physicians to almost one million professionals. Net Medical said that it will see multiple programs this year. This includes new insurance companies, global customers, and physicians who will be providing service for LGBT, HIV and Dermatology patients. At present, this division is recruiting an additional 175 physicians.

Furthermore, Net Medical Xpress has collaborated with a developing domestic and international Telehealth and Telemedicine company (TelePlus Health Care). TelePlus is a complete Telehealth solution. It addresses all the major health care issues. Net Medical and TelePlus have partnered with the leading specialists in the nation that specialize in Chronic Care, Diabetes, Primary Care, Mental Health, substance abuse and follow up care all integrated on a single secure portable electronic medical record.

Net Medical Xpress Solutions, Inc. (NMXS), closed Friday's trading session at $0.137, up 5.38%, on 1,544 volume with 3 trades. The average volume for the last 60 days is 6,329 and the stock's 52-week low/high is $0.0446/$0.375.

Vitaxel Group Limited (VXEL)

MarketWatch, OTC Markets Group, and Bloomberg reported on Vitaxel Group Limited (VXEL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Vitaxel Group Limited is a multi-level marketing (MLM) direct seller. The Company’s focus is on travel, entertainment, as well as lifestyle products and services. Vitaxel has three operating subsidiaries: Vitaxel SDN BHD (Vitaxel) and Vitaxel Online Mall SDN BHD (VMALL), and Vitaxel Singapore PTE. Ltd. Vitaxel is based in Kuala Lumpur, Malaysia and the Company lists on the OTCQB.

Vitaxel, through its subsidiaries, sells the abovementioned travel, entertainment, and lifestyle products and services via electronic commerce shopping platforms. Its VMALL is a multi-functional e-commerce network platform. VMALL engages in the development of online shopping platforms geared to Vitaxel and its members and third party providers of products and services.

Vitaxel combines e-commerce with network marketing. With the introduction of VMALL, the Company’s revenue component has been divided into three categories: Vitaxel Product packages; Membership Fees; and Sales from its online VMALL products.

Through its wholly-owned subsidiary, Vitaxel SDN BHD, Vitaxel Group launched a new Multi-Level Marketing (MLM) program on January 2, 2016, covering most of Southeast Asia. Vitaxel has over 5,200 distributors in more than 16 countries in Asia.

Successful sales consultants are expected to become shareholders of Vitaxel Group through the grant of equity incentive awards. The anticipation is that the important growth engine for Vitaxel will be the incentive program, as this program motivates team leaders to compete for sales consultant positions.

Vitaxel has its Vspark service, which concentrates on making money transfers easy. A client can conveniently manage their remittance business with Vspark. Features of Vspark include market leading exchange rates, enterprise grade security, business analytics, compliance automation, referral opportunities, and a competitive commission structure.

Also, Vitaxel has its VAPP. This is a custom-made platform for the Company’s fellow members to keep updated with the latest VITAXEL news, future VITAXEL events, monitoring VPOINT and their network activities.

Concerning products, Vitaxel has its Vitaxel Amalaki. This is a whole food product that combines a unique blend of Indian Gooseberries, PhytocellTec™ Solar Vitis and L-Glutathione. In addition, the Company has its Vzore, a skin formula with key ingredients that include Betula Alba Bark (White Birch); Tussilago Farfara Leaf Extract (Coltsfoot); Thymus Vulgaris (Thyme) Flower/Leaf Extract; and Equisetum Arvense Leaf Extract (Horsetail).

Vitaxel Group Limited (VXEL), closed Friday's trading session at $0.0117, down 2.50%, on 5,166,500 volume with 16 trades. The average volume for the last 60 days is 187,804 and the stock's 52-week low/high is $0.01/$0.06.

Force Protection Video Equipment Corp. (FPVD)

Promotion Stock Secrets, AimHighProfits, and Insider Financial reported earlier on Force Protection Video Equipment Corp. (FPVD), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Force Protection Video Equipment Corp. sells high definition (HD) body camera systems and accessories for law enforcement. The Company previously went by the name Enhancer-Your-Reputation.Com, Inc. It changed its name to Force Protection Video Equipment Corp. in March of 2015. The Company has its headquarters in Cary, North Carolina.

Force Protection offers its LE10 Law Enforcement Video Recorder product. The LE10 is a small bodyworn HD camera that is half the size and half the price of most law enforcement cameras now on the market. The LE10 has many features including still picture ability 8MP, WIFI, 4x zoom and audio recording. The LE10 does not require special software or expensive storage contracts.

The Company has its camera system for Law Enforcement and Security Agencies. The design of the C1, Citadel camera system is to combat and deter graffiti, illegal dumping and other property crimes. This self-contained system is solar powered. The C1 Citadel can be easily relocated between problem locations and no external power is needed. The Citadel Solar Security Camera is ideal for any surveillance application.

Force Protection released the LE50 HD Bodycam in 2016. The LE50 is a state-of-the-art designed body camera. It is strategically built around Ambarella chip sets (AMBA). Important design features of the LE50 include industry leading record time (10 hours @1080,12 hours @720); 50 hours of standby time; 32GB of internal tamperproof storage; and white LED illumination. Important design features also include audio announcements; GPS recording; 30 second pre-and post-record; and integration with VeriPic© Evidence Management Software.

The Company has also released the LE100 and LE101 1080 HD in car video recording dashcam systems. The LE100 and 101 are state-of-the-art designed in-car dash camera systems strategically built around Ambarella A7 chip sets (AMBA).

Force Protection Video Equipment has received FCC, IC and CE certification for the LE50 HD on the body video recorder. This past January, the Company announced that it received orders from an Indian nation in Arizona, an additional stocking order from its global distributor and from multiple local law enforcement for LE50 and LE10 on the body camera systems.

In addition, in February, the Company announced that it received an additional order for LE50 HD body cameras from its exclusive European distributor. The LE50 is CE compliant, a requirement for sales of electronics in the European Union.

Force Protection Video Equipment Corp. (FPVD), closed Friday's trading session at $0.0034, up 3.03%, on 13,101,764 volume with 95 trades. The average volume for the last 60 days is 4,511,246 and the stock's 52-week low/high is $0.0023/$0.29

American Housing Income Trust, Inc. (AHIT)

We are highlighting American Housing Income Trust, Inc. (AHIT) today, here at the QualityStocks Daily Newsletter.

American Housing Income Trust, Inc. (AHIT) owns, operates, and develops real estate assets in three western states. The Company operates out of its wholly-owned subsidiary American Realty Partners, LLC (Phoenix, Arizona). AHIT is a fully integrated and internally managed real estate investment company. Its emphasis is on the acquisition and management of single-family properties in select communities across the nation.

AHIT’s shares trade on the OTC Markets Group’s OTCQB. The Company incorporated as a Maryland Public Company in 2015 with the intention to elect REIT (Real Estate Investment Trust) status.

Moreover, IX Biotechnology, Inc. (a Wyoming corporation) is a wholly-owned subsidiary of AHIT. IX Biotechnology is implementing its business plan to become the largest producer of certified organic cannabidol oil in the U.S. This subsidiary’s plan is on being a fully integrated seed-to-shelf certified organic biotech enterprise.

AHIT concentrates on the acquisition, renovation, leasing, and management of single-family properties for rental income and long-term capital appreciation. The Company has a centralized operating platform. It has a fully internalized operating and property management platform and a strong local and regional leasing and management infrastructure.

AHIT has a wide-ranging history as real estate investment managers. The Company is internally managed with extensive private real estate company experience. AHIT’s focus and strategy remains the Phoenix market.

The Company has a disciplined acquisition strategy. This strategy includes a focus on markets with strong job growth, population in-migration and dynamic underlying economic fundamentals. AHIT looks for strong rental demand with the potential for considerable rent growth and home price appreciation.

AHIT’s strategy also involves capitalizing on an all sourcing channel (MLS, portfolio, auction). In addition, AHIT’s strategy is to target newer homes with 3-4 bedrooms in good school districts with family-oriented communities. For operational efficiency, the Company has in-house property inspectors, leasing teams, as well as maintenance technicians.

In November 2016, AHIT announced the implementation of a Cloud-Based End-to-End Property Management Automation System. The expectation is that this system will lessen the cost of managing the properties in the Company’s portfolio. 

The proprietary system is called AHIT Advantage. It will track all aspects of the property life-cycle. This includes property acquisition, tenant relations, rent payments and processing, maintenance requests, as well as property sales.

This week, AHIT announced that it closed its Stock Exchange Agreement with the above-mentioned IX Biotechnology. With this closing, AHIT restructured its Board of Directors resulting in Mr. Michael Ogburn being appointed its new Chairman of the Board, Chief Executive Officer and Chief Financial Officer. AHIT also appointed two new directors, Mr. Joaquin Flores and Mr. Brian Werner.

American Housing Income Trust, Inc. (AHIT), closed Friday's trading session at $0.7679, up 18.14%, on 420 volume with 2 trades. The average volume for the last 60 days is 2,576 and the stock's 52-week low/high is $0.35/$7.00.


The QualityStocks
Company Corner


India Globalization Capital, Inc. (IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital, Inc. (NYSE: IGC). Today, India Globalization Capital, Inc. closed trading at $0.4439, up 7.43%, on 911,465 volume with 1,171 trades. The stock’s average daily volume over the past 60 days is 177,968, and its 52-week low/high is $0.19/$0.6701.

India Globalization Capital, Inc. (IGC) is a first mover in developing a portfolio of products using cannabis-based "combination therapies" for the treatment of pain and other conditions.

The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion. IGC's patent filing (IGC-501) is a cannabis-based formulation addressing neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. The Company anticipates commencing clinical trials, and hopes that through its focus on combination therapy it can formulate and commercialize cannabinoid compounds as an alternative to long-term addictive opioid treatments.

The Company has also filed combination therapy formulations for the treatment of epilepsy and cachexia. About 50 million people worldwide are affected by epilepsy and about 1.3 million in the U.S. experience cachexia associated with cancer, MS, Parkinson's, HIV/AIDS and other progressive illnesses. Cancer-induced anorexia/cachexia is responsible for 20% of all cancer deaths. IGC-502 indicated for seizures and IGC-504 indicated for cachexia are unique combination therapies that, if proven out by clinical trials, are expected to treat medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional mono therapies.

IGC's strategy is exciting and unique in that it is aiming to become a leader in the phytocannabinoid-based combination therapy specialty pharmaceutical sector. This first mover advantage can potentially be formidable as it begins clinical trials and further builds its patent portfolio. "The development of combination therapies utilizing cannabis represents a large, unique opportunity in this emerging specialty-pharmaceutical sector. Securing FDA approval for combination therapy is believed to be significantly faster and less expensive than new drug applications. As a result, we believe that we can bring our cannabis-based pharmaceutical products to market in both an expeditious and cost-effective manner," stated Ram Mukunda, CEO.

IGC has recently exited its legacy businesses and currently holds international investments in land and in a hotel project. An impressive and experienced team, led by Mr. Ram Mukunda, CEO, directs IGC.

Mr. Mukunda holds degrees in Electrical Engineering and Mathematics from the University of Maryland (UMD). He founded and served as Chairman and CEO of Startec Global Communications, an international telecommunications carrier focused on providing voice over Internet protocol (VOIP) services to emerging economies. Startec, the first pure play international long distance carrier, went public on NASDAQ. He has won a number of awards, including the 2013 University of Maryland International Alumnus of the year award. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering, and has served as Council Member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda and Dr. Krishna are the originators of all the IGC patent filings.

Dr. Ranga Krishna, Senior Advisor, is a Board Certified Neurologist with a sub specialty in Epilepsy surgery. He is the Director of Neurology at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College and the Director of Stroke Service at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College. He is the Medical Director and Chairman of Total Neuro Care, P.C. He is CEO of International Pharma Trials, Inc., which assists U.S. pharmaceutical companies perform Phase II clinical trials. Dr. Krishna is a member of several organizations, including the American Academy of Neurology and the Medical Society of the State of New York. He is also a member of the Medical Arbitration panel for the New York State Workers' Compensation Board and a Founding Member of the New York State Pain Society. Dr. Krishna was trained at New York's Mount Sinai Medical Center (1991-1994) and New York University (1994-1996). Dr. Krishna and Mr. Mukunda are the originators of all the IGC patent filings. Disclaimer

India Globalization Capital, Inc. Company Blog

India Globalization Capital, Inc. News:

NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) CEO Featured in Benzinga Article

IGC Announces Third Quarter Financial Results

India Globalization Capital Announces the Extension of Warrants’ Expiry Date and Inducement Grant to its CFO

InMed Pharmaceuticals, Inc. (IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.289, up 5.86%, on 336,426 volume with 158 trades. The stock’s average daily volume over the past 60 days is 835,828, and its 52-week low/high is $0.05/$0.4261.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

NetworkNewsWire Announces Publication of Discussion on the R&D of Cannabinoids for Medical Use

InMed Pharmaceuticals Files PCT Patent for Epidermolysis Bullosa Simplex

InMeds Bioinformatics Platform Powers Cannabinoid Drug Development -- CFN Media

Monaker Group, Inc. (MKGI)

The QualityStocks Daily Newsletter would like to spotlight Monaker Group, Inc. (MKGI). Today, Monaker Group, Inc. closed trading at $3.10, up 5.08%, on 23,928 volume with 41 trades. The stock’s average daily volume over the past 60 days is 6,887, and its 52-week low/high is $1.33/$4.35.

Monaker Group, Inc. (MKGI) is a technology driven travel company focused on leveraging resources to become a significant presence in the fastest growing sector of the $1.3 trillion travel and tourism market. The company's flagship brand, NextTrip.com, is the industry's first and only real-time booking engine that features alternative lodging (vacation home rentals, resort residences and unused timeshare inventory), as well as a full selection of airlines, hotels, cruises, rental cars, tours and concierge services. These features are combined into a single, easy-to-use platform that gives travelers complete real-time control when planning and booking their vacations.

NextTrip.com takes an integrated approach to the needs of travelers by combining multiple booking solutions into a highly intuitive real-time booking platform. Since its launch in February 2016, NextTrip has already grown to more than 250,000 units of vacation rental inventory. Monaker currently has roughly 1 million additional alternative lodging units under contract that will soon be added to the platform. This will place NextTrip among the top three largest vacation rental inventories and rival industry peers, Airbnb and HomeAway, in the rapidly expanding alternative lodging market. Unlike the competition, which book by request which can take hours or days before a lodging owner confirms, NextTrip's platform books in real-time, similar to online hotel bookings.

Most NextTrip listings are in desirable locations in the U.S., the EU and the Caribbean with about 20% exclusive listings. Monaker expects rapid exclusive listing growth because, unlike the competition, Monaker doesn't charge a sign-up fee, just a commission upon booking. The competition charges both. Monaker even has a proprietary solution to unlock Timeshare and Fractional Share properties as rental inventory.

Through strategic partnerships and acquisitions Monaker is now positioned to be a major player in the travel and alternative lodging sector. In addition Monaker is also the parent to Maupintour and Voyage TV.

In business for 65 years, Maupintour still leads the tour industry in the creation of outstanding, unique itineraries and has the highest repeat rate in the tour industry. Maupintour's upscale luxury services create a unique blend with the various product offerings of NextTrip. Voyage TV has thousands of hours of travel footage shot in over 30 countries worldwide. These 15,000 video clips of hotels, resorts, cruise, and destination activities are a treasure trove for vacation travel marketing.

With an established portfolio of travel brands, and a proven record acquiring, consolidating and integrating companies, Monaker is building a diverse and exciting foundation to drive the company's future. According to data from the U.S. Travel Association, direct spending on leisure travel by domestic and international travelers topped $650 billion in 2015. When combined with the fact that roughly 64 percent of travel companies are still considered small businesses, Monaker's all-inclusive approach to vacation booking through NextTrip and Maupintour strategically positions it for sustainable growth moving forward.

Monaker is headquartered in South Florida with offices in California. The company is led by a seasoned management team with decades of applicable industry experience. Monaker's Chairman and Chief Executive Officer Bill Kerby has over 18 years of experience in the media and travel industries, as well as 10 years of experience in the financial industry. Disclaimer

Monaker Group, Inc. Company Blog

Monaker Group, Inc. News:

Monaker Group to Present at the 29th Annual ROTH Conference, March 15, 2017

Monaker Group Appoints Robert Post to Board of Directors

Monaker Group Appoints Simon Orange to Board of Directors Appointment Advances Monaker's Plans for NASDAQ Listing

GreenStone Healthcare Corp. (GRST)

The QualityStocks Daily Newsletter would like to spotlight GreenStone Healthcare Corp. (GRST). Today, GreenStone Healthcare Corp. closed trading at $0.0353, up 3.52%, on 98,246 volume with 8 trades. The stock’s average daily volume over the past 60 days is 67,587, and its 52-week low/high is $0.015/$0.083.

GreenStone Healthcare Corp. (GRST), through its subsidiaries, offers addiction and mental health rehabilitation treatments for residents, including out-patient counseling, coaching, intervention, psychological assessment, and other related services. The company recently sold its Canadian addiction treatment operations and acquired a U.S. based treatment center in Delray Beach, Florida, a major U.S. center for drug treatment programs located between Palm Beach and Miami. The company sought to expand into the U.S., where it could revolutionize treatment in that country with the skills it acquired in Canada. The company, through a subsidiary, will own and lease their assets in Canada, offering a stable secondary cash flow. Their newly acquired U.S. treatment center will be operated through a Florida limited liability company named Seastone Delray Healthcare LLC.

More than two thirds of families have been touched by a family member's addiction to alcohol, drugs, sex, and/or gambling. The addiction treatment market in the U.S. is estimated at over $35 billion annually, with a greater need than there are facilities. In addition, the GreeneStone approach differentiates itself in a number of ways:

  • Residents are treated holistically, taking into consideration all factors that can feed addiction, rather than the isolated treatment of addiction alone. Upon admission, all residents are fully assessed by professionals of a multidisciplinary team to develop an overall holistic treatment plan. An assembled team of best-in-class experts, including psychiatrists, physicians, nurses, and clinicians, manage and support residents who have co-occurring disorders such as depression, anxiety, and trauma.
  • Support is available both before and after resident treatment. Families can receive intervention support prior to admission, an often critical time for families and patients. Follow-up treatment support is available, to ensure progress and minimize the incidence of relapse. Families and others that are integral to the recovery are encouraged to participate in counseling and education sessions for continued success after in-patient treatment.

In addition to his experience with GreeneStone Healthcare, company president Shawn Leon has more than 25 years of experience managing public and private development-stage companies for various industries. He has provided financing and capital markets oversight for a number of these ventures, many of which have involved negotiations for mergers and acquisitions. Disclaimer

GreenStone Healthcare Corp. Company Blog

GreenStone Healthcare Corp. News:

GreeneStone Buys Canadian Real Estate Assets, Sells Canadian Addiction Treatment Business, and Acquires Addiction Treatment Business in Florida

GreeneStone Signs Definitive Agreement to Acquire Seastone of Delray, a Florida Limited Liability Company

GreeneStone Signs LOI to Acquire Aurora Recovery

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX). Today, ChineseInvestors.com closed trading at $1.37, up 1.48%, on 58,865 volume with 85 trades. The stock’s average daily volume over the past 60 days is 203,241 and its 52-week low/high is $0.12/$2.75.

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com Blog

ChineseInvestors.com News:

SeeThruEquity Issues Update on ChineseInvestors.com Inc. (OTCQB: CIIX), Increasing Price Target to $3.75

ChineseInvestors.com, Inc. to Present at the National Investment Banking Association Conference in New York City on February 28, 2017

ChineseInvestors.com Presents at Yibao Biologics' Annual Conference, Optimistic About Direct Selling Opportunity in China


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Penny Stock Prodigy
(HPIL) +54.55%


(CHEKW) +41.03%


Fortune Stock Alerts
(DMCD) +25.00%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251